ORIC Pharmaceuticals Reports $41.5 Million Net Loss in Q2 2026

ORIC Pharmaceuticals, Inc. reported a net loss of $41.5 million for the second quarter of 2026, compared to a net loss of $36.4 million for the same period in 2025, reflecting an increase of $5.1 million. For the first half of 2026, the company recorded a net loss of $77.3 million, up from $66.4 million in the prior year. Total operating expenses for the second quarter were $45.3 million, a rise from $39.1 million year-over-year, driven primarily by increased research and development costs associated with the advancement of its lead product candidates, rinzimetostat and enozertinib.

Research and development expenses for the second quarter of 2026 were $36.3 million, up from $30.5 million in the same quarter of 2025, marking a $5.7 million increase. This rise was attributed to higher external expenses related to rinzimetostat, which were partially offset by reduced costs for enozertinib due to timing differences in manufacturing and clinical activities. General and administrative expenses also saw a slight increase, totaling $9.0 million for the second quarter, compared to $8.5 million in the previous year, primarily due to higher professional service costs.

As of June 30, 2026, ORIC's total assets amounted to $404.7 million, a decrease from $408.9 million at the end of 2025. The company’s cash and cash equivalents stood at $37.5 million, down from $45.7 million at the end of the previous fiscal year. The decrease in cash was primarily due to the net loss incurred during the period, although the company raised approximately $59.9 million through an at-the-market offering during the first half of 2026, selling 4.7 million shares at an average price of $12.96.

Strategically, ORIC has focused its resources on advancing its two lead clinical programs, rinzimetostat and enozertinib, following a pipeline prioritization initiative announced in August 2025. This decision led to a workforce reduction of approximately 20% and a one-time cost of $1.9 million related to termination benefits. The company has also entered into clinical trial collaboration agreements with Bayer and Johnson & Johnson to support the development of its product candidates. Looking ahead, ORIC anticipates continued significant losses as it progresses through clinical trials and seeks regulatory approvals for its therapies, with expectations that its current financial resources will sustain operations into the second half of 2028.